Research Advances in Brain Metastasis

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 1689

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory of Lipid Metabolism and Cancer, Biomedical Group, Campus Gasthuisberg, KU Leuven, 3000 Leuven, Belgium
Interests: cancer imaging; artificial intelligence; radiomics; brain metastasis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The distinct microenvironment in the brain, including the existence of a disrupted blood–brain barrier (BBB), dense cellularity, etc., poses a demanding requirement for clinical diagnosis and treatment of brain metastasis (BM). BM is common in cancer patients, especially in lung cancer, breast cancer and melanoma, and is associated with high mortality. Lack of mandatory screening and reporting may lead to underestimated incidence. Regarding treatment, local treatments such as surgery and radiotherapy (WBRT, SBRT) are only eligible for selected patients, due to the widespread nature of BM and treatment-related complications. The delivery of systemic treatment is hurdled by the BBB, and repurposing of temozolomide in BM has not been validated in large randomized controlled trials. Emerging immune checkpoint inhibitor represents a novel option, yielding long-term response in some cases, and biomarkers to identify eligible patients are under exploration.

These clinical scenarios highlight a pressing need for research development in both preclinical and clinical settings. With the development of research methodology, bioinformatic, radiomic, metabolomics and multiomic on top of these provide a better understanding of the BM and ultimately aid in advancing BM diagnosis and treatment. Hopefully, technically solid and clinically relevant studies on BM may help improve patients’ care.

Dr. Shuncong Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain metastasis
  • precision medicine
  • bioinformatics
  • artificial intelligence
  • multiomic

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 2207 KiB  
Article
DenseNet_ HybWWoA: A DenseNet-Based Brain Metastasis Classification with a Hybrid Metaheuristic Feature Selection Strategy
by Abdulaziz Alshammari
Biomedicines 2023, 11(5), 1354; https://doi.org/10.3390/biomedicines11051354 - 04 May 2023
Cited by 1 | Viewed by 1379
Abstract
Brain metastases (BM) are the most severe consequence of malignancy in the brain, resulting in substantial illness and death. The most common primary tumors that progress to BM are lung, breast, and melanoma. Historically, BM patients had poor clinical outcomes, with limited treatment [...] Read more.
Brain metastases (BM) are the most severe consequence of malignancy in the brain, resulting in substantial illness and death. The most common primary tumors that progress to BM are lung, breast, and melanoma. Historically, BM patients had poor clinical outcomes, with limited treatment options including surgery, stereotactic radiation therapy (SRS), whole brain radiation therapy (WBRT), systemic therapy, and symptom control alone. Magnetic Resonance Imaging (MRI) is a valuable tool for detecting cerebral tumors, though it is not infallible, as cerebral matter is interchangeable. This study offers a novel method for categorizing differing brain tumors in this context. This research additionally presents a combination of optimization algorithms called the Hybrid Whale and Water Waves Optimization Algorithm (HybWWoA), which is used to identify features by reducing the size of recovered features. This algorithm combines whale optimization and water waves optimization. The categorization procedure is consequently carried out using a DenseNet algorithm. The suggested cancer categorization method is evaluated on a number of factors, including precision, specificity, and sensitivity. The final assessment findings showed that the suggested approach exceeded the authors’ expectations, with an F1-score of 97% and accuracy, precision, memory, and recollection of 92.1%, 98.5%, and 92.1%, respectively. Full article
(This article belongs to the Special Issue Research Advances in Brain Metastasis)
Show Figures

Figure 1

Back to TopTop